Amoebiasis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Giardiasis, Bacterial vaginosis, Acute necrotising ulcerative gingivitis, Acute dental infections, Prophylaxis of postoperative anaerobic bacterial infections, Eradication of H. pylori associated with peptic ulcer disease, Leg ulcers and pressure sores., Bacterial infections ,Parasitic infections
|Country of origin||
Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection., Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, and Neonates.
GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Anaphylaxis.
History of hypersensitivity to metronidazole or other nitro-imidazole derivatives. Pregnancy and lactation.